Kuanyshbek A 1
1. Assessment of complications incidence in post cardiac surgery patients who developed heparin induced thrombocytopenia
2. Prospective, Randomized Study of Fibrinogen Concentrate Versus Cryoprecipitate for Correcting Hypofibrinogenemia in Cardiac Surgery Patients
3. Enhanced Donor Lung Viability During Prolonged Ex Vivo Lung Perfusion Using ECMO Technology
4. Four-year follow-up after prophylactic awake peripheral veno-arterial ECMO during transcatheter aortic valve replacement
5. Cardiac Surgery Associated Acute Kidney Injury, Incidence, and Predictors. Prospective Observational Single Center Study
6. Impact of extracorporeal haemoadsorption during prolonged cardiopulmonary bypass on the incidence of acute kidney injury
7. Successful Heart Transplantation After 7 h of Cold Storage and Paracorporeal Donor Heart Resuscitation
8. Hemadsorption in patients requiring V-A ECMO support: Comparison of Cytosorb versus Jafron HA330
9. Prophylactic Awake Peripheral V-A ECMO during TAVR
10. Heparin Resistance in Patients Receiving Extracorporeal Membrane Oxygenation: A Review
11. Impact of Ventilation Discontinuation During Cardiopulmonary Bypass: A Prospective Observational Study
12. Surgical correction and postoperative period management of a patient with the giant left atrium: case report
13. Successful heart transplantation after 17 h ex vivo time using the Organ Care System—3 years follow-up
14. Case report: Transcatheter tricuspid valve-in-valve implantation using novel balloon-expandable aortic valve with 1 year follow-up
15. Case report: A novel surgical technique for rapid valve-in-ring implantation into the native aortic annulus during left ventricular assist device implantation
16. Mortality predictors of hospitalized patients with COVID-19: Retrospective cohort study from Nur-Sultan, Kazakhstan
17. Response to the manuscript “ex vivo donor heart preservation in heart transplantation (HTx)—Is this the solution to increase the donor pool?”
18. Detection and genomic characterization of an avian influenza virus A/mute swan/Mangystau/1-S24R-2/2024 (H5N1; clade 2.3.4.4b) strain isolated from the lung of a dead swan in Kazakhstan
19. Evaluation of commercial vaccines for efficacy and transmission control against the emergent H5N8 (clade 2.3.4.4b) avian influenza virus in Kazakhstan
20. Evaluation of safety, immunogenicity, and efficacy of inactivated reverse-genetics-based H5N8 highly pathogenic avian influenza virus vaccine with various adjuvants via parenteral and mucosal routes in chickens
1